Current Issue
VOL 11 NO 5 • JULY 2020
This issue’s cover illustration depicts diffuse large B-cell lymphoma and the novel agent polatuzumab vedotin. Polatuzumab vedotin is an antibody-drug conjugate comprising a cytotoxin bound to a monoclonal antibody that binds to CD79b on the B-cell tumor surface, inhibiting division and inducing apoptosis. Cytotoxin is indicated in red. Artwork by Alexandra Webber Baker © 2020, DNA Illustrations, Inc., Asheville, North Carolina.Research and ScholarshipAimee Strong,(1) DNP, RN, AGACNP-BC, and Michelle Renaud,(2) RN, PhDAccording to the American Cancer Society (2020), lung cancer is the leading cause of adult cancer-related deaths in the United States, with approximately 228,820 new cases and 135,720 deaths predicted in 2020. The National Lung Screening Trial reported that annual low-dose CT of the chest (LDCT) ...
Research and ScholarshipAnna Cathy Williams, RN, PhD, PHN, EdPhase I trials are rigorous treatments, and geriatric patients are extremely vulnerable to the known and unknown side effects of treatments (McMahon, Decker, & Ottery, 1998). Nutrition plays a major but not always fully understood role in many aspects of cancer development and treatment. Nutr...
Review ArticleRita J. Wickham, PhD, RNOver the past 40 years, major advances in knowledge and new drugs targeting chemotherapy-induced nausea and vomiting (CINV) have been incorporated into (largely) evidence-based antiemetic guidelines. Conversely, there is a thin evidence base underpinning guidelines for the palliative management o...
Review ArticleCarol Guarnieri, RN, MSN, FNP-C, and Daniel D. Von Hoff, MD, FACP, FASCO, FAACRCancer is the second most common cause of death in the United States, exceeded only by heart disease, and accounts for nearly one out of four deaths (American Cancer Society, 2018). Age is the greatest risk factor for developing cancer. Approximately 60% of people who have a diagnosis of cancer a...
Grand RoundsKarlyn L. Rupert, MPAS, PA-C, and Andrea J. Fehl, CRNP, AOCNP®Case Study
LB is a 51-year-old postmenopausal female with no significant past medical history who presented to the emergency department with a fungating breast mass. She delayed seeking medical care, as she was the primary caregiver for her daughter with developmental delays. Staging CT scans of ...
Practice MattersMaryAnn Fragola, ANP-C, DNPMany new treatment regimens have become available for patients with malignancies, particularly for patients with multiple myeloma (MM). As a result, MM has been increasingly described as a chronic illness. Newer modalities of treatment mean that patients must learn how to live with treatments whi...
Prescriber's CornerMelanie Douglas, MS, PA-C Lymphoma is the most common hematologic malignancy, accounting for 5% of newly diagnosed malignancies (Ku, Chong, & Hawkes, 2017; National Cancer Institute, 2019). In the United States, approximately 2.2% of individuals will be diagnosed with non-Hodgkin lymphoma (NHL) in their lifetime (Nati...
